Chemoradiotherapy for Advanced Esophageal Cancer

NCT02297217 | Recruiting Phase 2

• 1 other identifier: HREBA.CC-14-0122
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to show that the addition of carboplatin and paclitaxel chemotherapy to a palliative course of external beam radiation treatment improves both dysphagia relief and patient quality of life in patients with unresectable esophageal cancer.

Conditions

Esophageal Cancer

Outcome Measures

Primary Outcomes (1)

• Proportion of patients who achieve relief of dysphagia

  Will be measured as the proportion of patients who achieve relief of dysphagia, defined as improvement of at least one point on the Mellow Dysphagia Score, measured at Day 57 after the start of radiotherapy, and maintained for at least 28 calendar days (until the Day 85 visit).

  up to day 85

Secondary Outcomes (1)

• Dysphagia progression free survival

  6 Months

Study Arms (1)

Chemotherapy with Concurrent Radiation

EXPERIMENTAL

Carboplatin and paclitaxel will be administered intravenously on Days 1 and 8 while radiation therapy is administered

Drug: Carboplatin and Taxol (paclitaxel); Radiation: External Beam Radiation

Interventions

External Beam Radiation RADIATION

Patients will receive external beam radiation therapy of 30Gy/10 fractions over two weeks (or reduced to 25 Gy/10 fractions if acute toxicity parameters are met during the run-in) and receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Treatment will be planned, prescribed and delivered using standard 3D radiotherapy planning techniques to encompass the primary tumor and surrounding clinical target volume. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1.

Chemotherapy with Concurrent Radiation

Carboplatin and Taxol (paclitaxel) DRUG

Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1. Preparation and administration of chemotherapy will be according to local site standard of care.

Chemotherapy with Concurrent Radiation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Biopsy proven carcinoma of the esophagus.
• Not a candidate for radical/curative treatment due to the advanced nature of the disease, presence of metastases, or intercurrent illness.
• Symptomatic patients with Mellow Dysphagia Scores of ≥ 1 i.e. able to eat only some solids.
• ECOG Performance status ≤ 2.
• Patients able to begin treatment within 14 days of signing the informed consent form.
• Patient is at least 18 years old.
• Hematological function as defined by the following laboratory parameters:
• Hemoglobin \> 100g/L
• Platelet count \> 100x10E9/L
• Absolute neutrophil count \> 1.5x10E9/L
• Renal function to undergo chemotherapy as defined by the following laboratory parameters:
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x the upper limit of institutional normal (≤ 5 if liver metastases)
• Total bilirubin ≤ 1.5x the upper limit of institutional normal
• Calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault formula
• Patients capable of childbearing are using adequate contraception.

You may not qualify if:

• Previous radiotherapy delivered to the chest.
• Synchronous active malignancies.
• Pregnant or lactating patients: women of child bearing potential must have a negative serum pregnancy test within 7 days of Treatment Visit 1. Women or men of child bearing potential must use effective contraception (defined by the use of two birth control methods, which can be either two barrier methods or a barrier method plus a hormonal method to prevent pregnancy). Subjects must start using birth control from the time they have signed the Informed Consent Form prior to start of therapy until 120 days post completion of study therapy or study discontinuation, which must be documented in the eCRF.
• Patients unfit for any treatment component, including absolute contraindications for radiotherapy or Connective Tissue Disease.
• Tracheo-esophageal fistula.
• Esophageal stents in situ.
• Previous chemotherapy for esophageal cancer
• Unable to complete surveys in English without aid of interpreter.

Sponsors & Collaborators

• AHS Cancer Control Alberta: lead

Study Sites (1)

Tom Baker Cancer Centre

Calgary, Alberta, T2N 4N2, Canada

RECRUITING

MeSH Terms

Conditions

Esophageal Neoplasms

Interventions

Carboplatin; Paclitaxel

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Head and Neck Neoplasms; Digestive System Diseases; Esophageal Diseases; Gastrointestinal Diseases

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Diterpenes; Terpenes

Study Officials

• Marc Kerba, MD

  5872316617

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Marilyn David

CONTACT

5872315492; marilyn.david@cancercarealberta.ca

Amy Abel

CONTACT

amy.abel@albertahealthservices.ca

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: November 19, 2014
• First Posted: November 21, 2014
• Study Start: November 21, 2019
• Primary Completion (Estimated): April 30, 2027
• Study Completion (Estimated): April 30, 2028
• Last Updated: December 16, 2025

Record last verified: 2025-10

Locations

CA (1)